Dudediligence.

INmune Bio Inc

INMBNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Dec ’24$50,000Mar ’25$0.00Dec ’25
Net income, by quarter
−$12.1MSep ’24−$9.2MDec ’24−$9.7MMar ’25−$24.5MJun ’25−$6.5MSep ’25−$5.3MDec ’25−$5.4MMar ’26−$1.3MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$181,000$374,000$155,000$14,000$50,000
Operating income−$29.2M−$26.0M−$29.7M−$42.6M−$47.4M
Net income−$30.3M−$27.3M−$30.0M−$42.1M−$45.9M
Operating cash flow−$28.5M−$22.7M−$12.0M−$33.4M−$22.6M
Free cash flownone on filenone on filenone on filenone on file−$23.6M
Cash$74.8M$52.2M$35.8M$20.9M$24.8M
Debtnone on file$14.7M$9.9Mnone on filenone on file
Shares outstanding17.8M17.9M18.0M22.3M26.6M